Topotecan hydrochloride hydrate
Based on 39 publication(s) in Google Scholar
Topotecan hydrochloride hydrate is an orally active and potent Topoisomerase I inhibitor. Topotecan hydrochloride hydrate induces cell cycle arrest in G0/G1 and S phases and promotes apoptosis. Topotecan hydrochloride hydrate shows anticancer activity.
For research use only. We do not sell to patients.
- CAS No.: 1044663-62-8
- Formula: C23H26ClN3O6
- Molecular Weight:475.92
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Topotecan hydrochloride hydrate
More- Cancer Res. 2023 Dec 15;83(24):4015-4029. [Abstract]
- J Extracell Vesicles. 2022 Apr;11(4):e12206. [Abstract]
- Nat Commun. 2025 Jun 2;16(1):5126. [Abstract]
- Nat Commun. 2019 Aug 21;10(1):3761. [Abstract]
- J Exp Clin Cancer Res. 2018 Dec 20;37(1):321. [Abstract]
- Adv Sci (Weinh). 2026 Jun 9:e23182. [Abstract]
- MedComm (2020). 2025 Nov 29;6(12):e70517. [Abstract]
- Cell Rep Med. 2025 Apr 15;6(4):102053. [Abstract]
- Pharmacol Res. 2024 Jun:204:107208. [Abstract]
- Cell Death Dis. 2024 Jan 18;15(1):66. [Abstract]
- Cell Commun Signal. 2024 Jun 13;22(1):325. [Abstract]
- Acta Pharmacol Sin. 2021 Jan;42(1):108-114. [Abstract]
- NPJ Precis Oncol. 2024 Jun 5;8(1):128. [Abstract]
- J Transl Med. 2024 Aug 14;22(1):766. [Abstract]
- Cancer Immunol Res. 2023 May 3;11(5):583-599. [Abstract]
- Cell Rep. 2025 Mar 25;44(4):115466. [Abstract]
- Cell Rep. 2025 Jan 11;44(1):115171. [Abstract]
- Pharmaceutics. 2022 Nov 24;14(12):2595. [Abstract]
- Eur J Med Chem. 2024 Dec 5:279:116842. [Abstract]
- Biochem Pharmacol. 2023 Oct:216:115769. [Abstract]
- J Biomed Inform. 2023 Jun:142:104383. [Abstract]
- Cell Rep Methods. 2023 Oct 23;3(10):100599. [Abstract]
- Int J Mol Sci. 2025 Apr 17;26(8):3790. [Abstract]
- J Mol Med (Berl). 2019 Aug;97(8):1183-1193. [Abstract]
- Sci Rep. 2019 Oct 22;9(1):15099. [Abstract]
- Cancers (Basel). 2021 Dec 31;14(1):193. [Abstract]
- J Cell Mol Med. 2026 Apr;30(7):e71101. [Abstract]
- Bioengineering (Basel). 2025 Oct 19;12(10):1121. [Abstract]
- J Virol. 2019 May 15;93(11):e02230-18. [Abstract]
- J Immunol. 2022 Jul 1;209(1):171-179. [Abstract]
- J Nat Prod. 2025 Mar 28;88(3):688-705. [Abstract]
- Phytochemistry. 2021 Nov:191:112910. [Abstract]
- FASEB Bioadv. 2020 Mar 7;2(4):254-263. [Abstract]
- bioRxiv. 2026 Mar 13.
- bioRxiv. 2025 Sep 21.
- Indiana University Indianapolis. 2025.
- bioRxiv. 2024 Jul 7:2024.07.04.601620. [Abstract]
- bioRxiv. 2023 Apr 14.
- Universitat Autònoma de Barcelona. 2022 Aug.
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
In Vivo Efficacy Study
-
Flow Cytometry
-
IF
-
WB
All Topoisomerase Isoforms
More
Biological Activity
|
Topoisomerase I |
Topotecan hydrochloride hydrate obviously inhibits proliferation of human glioma cells and glioma stem cells (GSCs) in a dose- and time-dependent manner[1].
Topotecan hydrochloride hydrate (0-40 μM) obviously inhibits the cell viability compared with the control groups, in a dose-dependent manner[1].
Topotecan hydrochloride hydrate shows anti-proliferation activity against U251, U87, GSCs-U251 and GSCs-U87 cells, with IC50 values of 2.73±0.25, 2.95±0.23, 5.46±0.41, and 5.95±0.24 μM, respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1044663-62-8
-
Molecular Weight 475.92
-
Formula C23H26ClN3O6
-
SMILES
O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=CC5=C(CN(C)C)C(O)=CC=C5N=C4C3=C2)=O.Cl.O
-
Synonyms
SKF 104864A hydrochloride hydrate; NSC 609669 hydrochloride hydrate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (39)
-
Journal Impact Factor
-
Most Recent
-
Cancer Res
Topoisomerase 1 Inhibition in MYC-Driven Cancer Promotes Aberrant R-Loop Accumulation to Induce Synthetic Lethality. [Abstract]2023 Dec 15;83(24):4015-4029. PMID: 37987734
Topotecan hydrochloride hydrate purchased from MedChemExpress. Usage Cited in: Cancer Res. 2023 Dec 15;83(24):4015-4029. [Abstract]
Topotecan hydrochloride (10 mg/kg; ip). Tumor weights from 10A.PM xenografts after Topotecan treatment.
-
J Extracell Vesicles
Analysis of extracellular vesicle DNA at the single-vesicle level by nano-flow cytometry. [Abstract]2022 Apr;11(4):e12206. PMID: 35373518
Topotecan hydrochloride hydrate purchased from MedChemExpress. Usage Cited in: J Extracell Vesicles. 2022 Apr;11(4):e12206. [Abstract]
Topotecan hydrochloride (20 μM; 48 h). Bivariate dot‐plots of SYTO 16 fluorescence versus EV size of EVs for EV preparations from HCT‐15 cells treated with DMSO control (i), etoposide (ii), SN‐38 (iii) or topotecan (iv).
-
Nat Commun
Selective targeting of genome amplifications and repeat elements by CRISPR-Cas9 nickases to promote cancer cell death. [Abstract]2025 Jun 2;16(1):5126. PMID: 40456709 -
Nat Commun
Genotoxic stress-triggered β-catenin/JDP2/PRMT5 complex facilitates reestablishing glutathione homeostasis. [Abstract]2019 Aug 21;10(1):3761. PMID: 31434880
Topotecan hydrochloride hydrate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2019 Aug 21;10(1):3761. [Abstract]
Topotecan (10 mg/kg; Intraperitoneal injection). Representative images and the apoptotic rate the indicated chemotherapy-treated xenograft tumors.
Topotecan hydrochloride hydrate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2019 Aug 21;10(1):3761. [Abstract]
Topotecan (10 mg/kg; Intraperitoneal injection). IB analysis of the level of cleaved-caspase 3 and cleaved-PARP1 in the indicated chemotherapy-treated xenograft tumors. GAPDH served as the loading control.
-
J Exp Clin Cancer Res
Arsenic trioxide reverses the chemoresistance in hepatocellular carcinoma: a targeted intervention of 14-3-3η/NF-κB feedback loop. [Abstract]2018 Dec 20;37(1):321. PMID: 30572915 -
Adv Sci (Weinh)
TME/NIR Dual-Responsive Zinc-Based Targeted Nanoagonist for Multimodal Amplification of STING-Mediated Cancer Immunotherapy. [Abstract]2026 Jun 9:e23182. PMID: 42261811 -
MedComm (2020)
KSQ-4279, an Inhibitor of Ubiquitin Specific Peptidase 1, Enhanced the Chemotherapeutic Efficacy in ABCB1/ABCG2/ABCC1-Mediated Multidrug Resistant Cancers. [Abstract]2025 Nov 29;6(12):e70517. PMID: 41328326 -
Cell Rep Med
CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]2025 Apr 15;6(4):102053. PMID: 40187357 -
Pharmacol Res
2024 Jun:204:107208. PMID: 38729587 -
Cell Death Dis
2024 Jan 18;15(1):66. PMID: 38238307 -
Cell Commun Signal
BI-2865, a pan-KRAS inhibitor, reverses the P-glycoprotein induced multidrug resistance in vitro and in vivo. [Abstract]2024 Jun 13;22(1):325. PMID: 38872211 -
Acta Pharmacol Sin
Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway. [Abstract]2021 Jan;42(1):108-114. PMID: 32398685 -
NPJ Precis Oncol
Targeting the DYRK1A kinase prevents cancer progression and metastasis and promotes cancer cells response to G1/S targeting chemotherapy drugs. [Abstract]2024 Jun 5;8(1):128. PMID: 38839871
Topotecan hydrochloride hydrate purchased from MedChemExpress. Usage Cited in: NPJ Precis Oncol. 2024 Jun 5;8(1):128. [Abstract]
Topotecan hydrochloride (0.0001-100 μM; 48 h). Dose-response curves after various concentrations of chemotherapeutic drugs in DYRK1A-KOs and NT-KOs for HCT-116 cell.
-
J Transl Med
DB-1314, a novel DLL3-targeting ADC with DNA topoisomerase I inhibitor, exhibits promising safety profile and therapeutic efficacy in preclinical small cell lung cancer models. [Abstract]2024 Aug 14;22(1):766. PMID: 39143619 -
Cancer Immunol Res
Discovery of podofilox as a potent cGAMP-STING signaling enhancer with antitumor activity. [Abstract]2023 May 3;11(5):583-599. PMID: 36921097 -
Cell Rep
Structural basis for the reversal of human MRP4-mediated multidrug resistance by lapatinib. [Abstract]2025 Mar 25;44(4):115466. PMID: 40138312 -
Cell Rep
miR-449a/miR-340 reprogram cell identity and metabolism in fusion-negative rhabdomyosarcoma. [Abstract]2025 Jan 11;44(1):115171. PMID: 39799567 -
Pharmaceutics
Encorafenib Acts as a Dual-Activity Chemosensitizer through Its Inhibitory Effect on ABCC1 Transporter In Vitro and Ex Vivo. [Abstract]2022 Nov 24;14(12):2595. PMID: 36559089 -
Eur J Med Chem
2024 Dec 5:279:116842. PMID: 39260319 -
Biochem Pharmacol
Tazemetostat synergistically combats multidrug resistance by the unique triple inhibition of ABCB1, ABCC1, and ABCG2 efflux transporters in vitro and ex vivo. [Abstract]2023 Oct:216:115769. PMID: 37634597 -
J Biomed Inform
2023 Jun:142:104383. PMID: 37196989 -
Cell Rep Methods
RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]2023 Oct 23;3(10):100599. PMID: 37797618 -
Int J Mol Sci
2025 Apr 17;26(8):3790. PMID: 40332396 -
J Mol Med (Berl)
2019 Aug;97(8):1183-1193. PMID: 31201471 -
Sci Rep
Drug-induced PD-L1 expression and cell stress response in breast cancer cells can be balanced by drug combination. [Abstract]2019 Oct 22;9(1):15099. PMID: 31641154 -
Cancers (Basel)
Targeted Disruption of E6/p53 Binding Exerts Broad Activity and Synergism with Paclitaxel and Topotecan against HPV-Transformed Cancer Cells. [Abstract]2021 Dec 31;14(1):193. PMID: 35008354 -
J Cell Mol Med
2026 Apr;30(7):e71101. PMID: 41896195 -
Bioengineering (Basel)
Precision Oncology for High-Grade Gliomas: A Tumor Organoid Model for Adjuvant Treatment Selection. [Abstract]2025 Oct 19;12(10):1121. PMID: 41155119 -
J Virol
Cellular DNA Topoisomerases Are Required for the Synthesis of Hepatitis B Virus Covalently Closed Circular DNA. [Abstract]2019 May 15;93(11):e02230-18. PMID: 30867306 -
J Immunol
Identification of RPL15 60S Ribosomal Protein as a Novel Topotecan Target Protein That Correlates with DAMP Secretion and Antitumor Immune Activation. [Abstract]2022 Jul 1;209(1):171-179. PMID: 35725272 -
J Nat Prod
Ingenane Diterpenoids from Euphorbia peplus as Potential New CHK1 Inhibitors That Sensitize Cancer Cells to Chemotherapy. [Abstract]2025 Mar 28;88(3):688-705. PMID: 40056138 -
Phytochemistry
2021 Nov:191:112910. PMID: 34481345 -
FASEB Bioadv
Effect of static magnetic field on DNA synthesis: The interplay between DNA chirality and magnetic field left-right asymmetry. [Abstract]2020 Mar 7;2(4):254-263. PMID: 32259051 -
-
-
-
bioRxiv
Rebalancing Viral and Immune Damage versus Tissue Repair Prevents Death from Lethal Influenza Infection. [Abstract]2024 Jul 7:2024.07.04.601620. PMID: 39372755 -
-
Purity & Documentation
References
[1]. Zhang FL, et al. PLoS One. 2013 Nov 26;8(11):e81815.Topoisomerase I inhibitors, Shikonin and Topotecan, inhibit growth and induce apoptosis of glioma cells andglioma stem cells. [Content Brief]
[2]. Kumar S, et al. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor. Clin Cancer Res. 2011 Sep 1;17(17):5656-67. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Topotecan hydrochloride hydrate Related Classifications
HY-13768C Related Classifications
Powered by Bioz